Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: NetraMark Holdings Inc.

Market Cap 74.2M 52.5M 45.74M 42.17M 39.66M 4.95B 74.72M 502M 195M 2.44B 197M 193M 8.45B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 74.2M 52.5M 45.74M 42.17M 39.66M 4.95B 74.72M 502M 195M 2.44B 197M 193M 8.45B EV / Sales 2026 *
185x
EV / Sales 2027 * -
Free-Float
89.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 52.89M
+0.35%-2.46%-20.72%+12.62% 2,815B
-1.25%-1.53%-7.78%+717.42% 313B
+14.20%+22.46%+291.79%+907.90% 123B
+0.95%+2.30%+32.25%+68.83% 107B
-1.40%-0.25%-3.90%+4.51% 88.41B
-1.76%-5.19%+70.79%+129.72% 80.67B
+0.81%+7.29%-40.95%+50.20% 55.64B
+6.09%+13.93%+1.31%+73.80% 42.34B
+8.64%+20.49%-48.95%+25.45% 34.38B
Average +2.67%+5.83%+30.43%+221.16% 406.61B
Weighted average by Cap. +0.77%-2.39%-5.47%+108.39%

Financials

2026 *2027 *
Net sales 401K 284K 247K 228K 214K 26.73M 404K 2.71M 1.05M 13.18M 1.06M 1.04M 45.67M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!